A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Latest Information Update: 13 Feb 2025
At a glance
- Drugs ERAS-801 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms THUNDERBBOLT-1
- Sponsors Erasca
Most Recent Events
- 10 Feb 2025 Planned primary completion date changed from 31 Jan 2025 to 30 Jun 2025.
- 17 May 2024 According to an Erasca media release, due to the desire to focus internal resources on developing naporafenib and the RAS-targeting franchise, Erasca is exploring further advancement of ERAS-801 via select investigator-sponsored trial(s).
- 27 Mar 2024 According to an Erasca media release, initial Phase 1 monotherapy data expected in 2024.